Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

20151,034 citationsJournal Articlebronze Open Access

Authors

Deborah Siegal · McMaster University

John T. Curnutte · Portola Pharmaceuticals (United States)

Stuart J. Connolly · McMaster University

Genmin Lu · Portola Pharmaceuticals (United States)

Pamela B. Conley · Portola Pharmaceuticals (United States)

Brian L. Wiens · Portola Pharmaceuticals (United States)

Vandana Mathur

Abstract

Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects. (Funded by Portola Pharmaceuticals and others; ANNEXA-A and ANNEXA-R ClinicalTrials.gov numbers, NCT02207725 and NCT02220725.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Blood Coagulation and Thrombosis Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 25, pp. 2413-2424

DOI: 10.1056/nejmoa1510991

Field-Weighted Citation Impact: 120.04